339-62-8

Basic information

• Product Name: 4,4,4-trifluoro-3-methylbutan-1-ol
• CAS NO: 339-62-8
• Molecular Formula: C₅H₉F₃O
• Molecular Weight: 142.1196
• Mol File: 339-62-8.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 78.7°C at 760 mmHg
• Flash Point: 43.8°C
• Density: 1.133g/cm³
• Vapor Pressure: 61.6mmHg at 25°C
• Refractive Index: 1.352
• CAS DataBase Reference: 4,4,4-trifluoro-3-methylbutan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4,4,4-trifluoro-3-methylbutan-1-ol(339-62-8)
• EPA Substance Registry System: 4,4,4-trifluoro-3-methylbutan-1-ol(339-62-8)

Safety Data

• Hazardous Substances Data: 339-62-8(Hazardous Substances Data)

Upstream product

• 348-75-4 (-)-3-trifluoromethylbutanoic acid 
• 6975-13-9 (+/-)-ethyl 4,4,4-trifluoro-3-methylbutanoate 
• 107103-94-6 2,3-bis(trifluoromethyl)butanoic acid 
• 691-77-0 (E)-3-trifluoromethyl-2-butenoic acid ethyl ester 
• 338-03-4 4,4,4-trifluoro-3-hydroxy-3-methyl-butanoic acid 
• 69056-67-3 3-methyl-4,4,4-trifluoro-2-butenoic acid 
• 59867-95-7 (E)-4,4,4-trifluoro-3-methylbut-2-en-1-ol 

Downstream Products

• 95853-69-3 (+/-)-4,4,4-Trifluor-3-methyl-1-butanal 

Relevant articles and documents

3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of hepatitis C virus RNA-dependent RNA polymerase

Recently, we disclosed a new class of HCV polymerase inhibitors discovered through high-throughput screening (HTS) of the GlaxoSmithKline proprietary compound collection. This interesting class of 3-(1,1-dioxo-2H-1,2,4- benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones potently inhibits HCV polymerase enzymatic activity and inhibits the ability of the subgenomic HCV replicon to replicate in Huh-7 cells. This report will focus on the structure-activity relationships (SAR) of substituents on the quinolinone ring, culminating in the discovery of 1-(2-cyclopropylethyl)-3-(1,1-dioxo-2H-1,2,4- benzothiadiazin-3-yl)-6-fluoro-4-hydroxy-2(1H)-quinolinone (130), an inhibitor with excellent potency in biochemical and cellular assays possessing attractive molecular properties for advancement as a clinical candidate. The potential for development and safety assessment profile of compound 130 will also be discussed.

Nonproteinogenic Amino Acids, II. - Synthesis and Determination of the Absolute Configuration of (2S,4S)-(-)- and (2S,4R)-(+)-5,5,5-Trifluoroleucine

The synthesis (Scheme 1) of racemic 4,4,4-trifluoro-3-methyl-1-butanol (5) and the resolution of its enantiomers is described.The absolute configuration of the negatively rotating enantiomer of 5 is correlated to that of the optically active fermentation amyl alcohol (S-10) via (S)-(-)-1,1,1-trifluoro-2-methylbutane (S-8) (Scheme 2).Oxidation of optically pure (R)-(+)-4,4,4-trifluoro-3-methyl-1-butanol (R-5) yields the aldehyde R-6 which is employed as starting material for the asymmetric Strecker synthesis of (2S,4R)-(+)-5,5,5-trifluoroleucine (13a).The analogous synthesis with (+/-)-4,4,4-trifluoro-3-methyl-1-butanol (6) via the aminonitrile 11 affords the optically pure (2S,4S)-diastereoisomer 11b which leads to enantiomerically pure (2S,4S)-(-)-5,5,5-trifluoroleucine (13b).